natgillin/translations-raw huggingface dataset:
Isentress fås også som en 400 mg tablet, en 600 mg tablet og som en tyggetablet.
Isentress is also available in a 400 mg tablet, a 600 mg tablet and in a chewable tablet.
1 ml (10 mg) to gange dagligt
1 mL (10 mg) twice daily
0,4 ml (4 mg) en gang dagligt
0.4 mL (4 mg) once daily
Tabel 4 Effektresultater ved uge 48 og 96
Table 4 Efficacy Outcome at Weeks 48 and 96
Geometrisk middelværdi (%CV†) AUC0-12t (μM●t)
Geometric mean (%CV AUC0-12hr (μM●hr)
Raltegravir 400 mg to gange dagligt (N = 266)
Raltegravir 400 mg twice daily (N = 266)
Gastritis, abdominale gener, øvre abdominal smerte, abdominal ømhed, anorektale gener, obstipation, mundtørhed, epigastrisk ubehag, erosiv duodenit, eructatio, gastroøsofageal refluks, gingivit, glossit, odynofagi, akut pankreatit, ulcus pepticum, rektalblødning
Uncommon abdominal distention, abdominal pain, diarrhoea, flatulence, nausea, vomiting, dyspepsia gastritis, abdominal discomfort, abdominal pain upper, abdominal tenderness, anorectal discomfort, constipation, dry mouth, epigastric discomfort, erosive duodenitis, eructation, gastroesophageal reflux disease, gingivitis, glossitis, odynophagia, pancreatitis acute, peptic ulcer, rectal haemorrhage
Hold flasken tæt tillukket og behold tørremidlet i flasken for at beskytte mod fugt.
Keep the bottle tightly closed, with the desiccant in order to protect from moisture.
Tal med lægen om andre lægemidler, du kan tage mod for meget mavesyre.
Talk to your doctor about other antacids you can take.
Tabel 2 Effektresultater ved uge 48 og 96
Table 2 Efficacy Outcome at Weeks 48 and 96
Dosisjustering af raltegravir (400 mg to gange dagligt og 1.200 mg en gang dagligt) eller hormonelle antikonceptionsmidler (østrogen- og/eller progesteronbaserede) er ikke nødvendig.
No dosage adjustment required for raltegravir (400 mg twice daily and 1,200 mg once daily) or hormonal contraceptives (estrogen- and/or progesterone-based).
Klik låget på blandebægeret på plads.
Snap the lid of the mixing cup shut.
Vend sprøjten med spidsen opad.
Hold the syringe with tip up.
ISENTRESS 100 mg granulat raltegravir
ISENTRESS 100 mg granules Raltegravir
Karakteristika ved baseline Hiv-RNA > 100.000 kopier/ml 86,7 (80,0; 91,8) 83,8 (73,4; 91,3) 84,7 (77,5; 90,3) 82,9 (72,0; 90,8) ≤ 100.000 kopier/ml 97,2 (94,9; 98,7) 97,7 (94,3; 99,4) 91,9 (88,5; 94,5) 93,0 (89,1; 97,1) CD4-celletal ≤ 200 celler/mm > 200 celler/mm Virusundertype Clade B Non-Clade B 93,6 (89,1; 96,6) 93,2 (84,9; 97,8) 89,5 (84,1; 93,6) 94,4 (86,2; 98,4)
≤ 100,000 copies/mL CD4-count ≤ 200 cells/mm > 200 cells/mm Viral Subtype Clade B Non-Clade B 93.6 (89.1, 96.6) 93.2 (84.9, 97.8) 89.5 (84.1, 93.6) 94.4 (86.2, 98.4)
Reduceret absolut neutrofilværdi, forhøjet alkalisk fosfatase, fald i albumin, forhøjet blodamylase, forhøjet bilirubin i blodet, forhøjet kolesteroltal, stigning i serumkreatinin, stigning i blodsukker, stigning i karbamidkvælstof, forhøjet kreatinfosfokinase, stigning i fasteblodsukker, sukker i urinen, stigning i HDL, forhøjet international normaliseret ratio (INR), stigning i LDL, fald i antal blodplader, positiv test for røde blodlegemer i urinen, øget abdominalomfang, vægtøgning, fald i antal hvide blodlegemer
Uncommon alanine aminotransferase increased, atypical lymphocytes, aspartate aminotransferase increased, blood triglycerides increased, lipase increased, blood pancreatic amylase increased absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased
Pres al luften ud af sprøjten ved at trykke stemplet langsomt opad.
Slowly push the plunger to make the air come out.
CCR5-hæmmere maraviroc (raltegravir 400 mg to gange dagligt)
CCR5 inhibitors maraviroc (raltegravir 400 mg Twice Daily)
Dosisjustering af raltegravir eller methadon er ikke nødvendig.
No dose adjustment required for raltegravir or methadone.
Tabletkerne - Mikrokrystallinsk cellulose - Lactosemonohydrat - Calciumphosphat, dibasisk, vandfrit - Hypromellose 2208 - Poloxamer 407 - Natriumstearylfumarat - Magnesiumstearat
Tablet core - Microcrystalline cellulose - Lactose monohydrate - Calcium phosphate dibasic anhydrous - Hypromellose 2208 - Poloxamer 407 - Sodium stearyl fumarate - Magnesium stearate
BENCHMRK 1 og BENCHMRK 2 (randomiserede, dobbeltblindede, placebokontrollerede multicenterstudier) vurderede sikkerheden og den antiretrovirale aktivitet af raltegravir 400 mg to gange dagligt versus placebo i en kombination med OBT hos hiv-inficerede patienter, i alderen 16 år og ældre, der har dokumenteret resistens over for mindst ét lægemiddel i hver af de 3 klasser (NRTIere, NNRTIere, PIere) af antiretroviral terapi.
BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled trials) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. placebo in a combination with optimised background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 drug in each of 3 classes (NRTIs, NNRTIs, PIs) of anti-retroviral therapies.
Raltegravir er blevet undersøgt hos 126 antiretrovirale behandlingserfarne hiv-1-inficerede børn og unge i alderen 2 til 18 år i kombination med andre antiretrovirale lægemidler i IMPAACT P1066 (se pkt.
Raltegravir has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 to 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
Ved den prognostiske analyse blev virologisk svigt analyseret som "carry forward" for procent med henholdsvis < 50 og 400 kopier/ml.
For analysis by prognostic factors, virologic failures were carried forward for percent < 50 and 400 copies/mL.
Administration af raltegravir sammen med aluminium- og/eller magnesiumholdige antacida frarådes derfor.
Therefore, co-administration of raltegravir with aluminium and/or magnesium containing antacids is not recommended.
ANTACIDA INDEHOLDENDE METALKATIONER antacidum med aluminium- og magnesiumhydroxid (raltegravir 400 mg to gange dagligt)
METAL CATION ANTACIDS aluminium and magnesium hydroxide antacid (raltegravir 400 mg Twice Daily)
11 til under 25 kg
11 to less than 25 kg Chewable tablet
Spædbørn og småbørn i alderen 4 uger til under 2 år Raltegravir to gange dagligt er også blevet undersøgt hos 26 hiv-1-inficerede spædbørn og småbørn i alderen 4 uger til under 2 år i kombination med andre antiretrovirale midler i IMPAACT P1066 (se pkt.
Infants and toddlers 4 weeks to less than 2 years of age Raltegravir twice daily has also been studied in 26 HIV-1 infected infants and toddlers 4 weeks to less than 2 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
ISENTRESS er, i kombination med andre antiretrovirale lægemidler, indiceret til behandling af infektion med humant immundefekt-virus (hiv-1) (se pkt.
ISENTRESS is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection (see sections 4.2, 4.4, 5.1 and 5.2).
Karton til ISENTRESS 100 mg granulat til oral suspension
Carton for ISENTRESS 100 mg granules for oral suspension
Hudproblemer
Skin problems
I dosisintervallet 100 mg-800 mg øgede raltegravir C12t proportionalt med dosis, men dosisproportionaliteten var lidt mindre end for dosisintervallet 100 mg-1.600 mg.
Raltegravir AUC and Cmax increase dose proportionally over the dose range 100 mg to 1,600 mg. Raltegravir C12 hr increases dose proportionally over the dose range of 100 to 800 mg and increases slightly less than dose proportionally over the dose range 100 mg to 1,600 mg.
Se produktresuméet for 600 mg tabletten for yderligere oplysninger om dosering.
Refer to the 600 mg tablet SmPCs for additional dosing information.
• Oppustethed, mavesmerter, diarré, usædvanlig meget luft i mave eller tarme, kvalme,
• bloating; abdominal pain; diarrhoea; excessive gas in the stomach or bowel; feeling sick;
Vægtbaseret dosering, se doseringstabellerne for tyggetabletten 13
Weight based dosing, see dosing Table 2 13
Opnået hiv-RNA <50 kopier/ml Gennemsnitligt CD4-celletal (%) stigning ift.
Achieved HIV RNA <50 copies/mL Mean CD4 cell count (%) increase from baseline
Isentress indeholder:
What Isentress contains
• Ledsmerter, smertefuld ledsygdom, rygsmerter, smerter i knogler/muskler, muskelømhed ellersvaghed, nakkesmerter, smerter i arme og/eller ben, senebetændelse, fald i knoglemineraler
• joint pain; painful joint disease; back pain; pain in bone/muscle; muscle tenderness or weakness; neck pain; pain in arms or legs; inflammation of the tendons; decrease in the amount of minerals in the bone
Behandlingsnaive voksne patienter (1.200 mg [2 x 600 mg] en gang dagligt) ONCEMRK (randomiseret, dobbeltblindet, aktivt kontrolleret multicenterstudie; Protokol 292) vurderede sikkerhed og antiretroviral aktivitet af raltegravir 1.200 mg en gang dagligt + emtricitabin (+) tenofovirdisoproxilfumarat versus raltegravir 400 mg to gange dagligt i kombination med emtricitabin (+) tenofovirdisoproxilfumarat hos behandlingsnaive hiv-inficerede patienter med hivRNA > 1.000 kopier/ml.
Treatment-naïve adult patients (1,200 mg [2 x 600 mg] once daily) ONCEMRK (multi-centre, randomised, double-blind, active-control trial; Protocol 292) evaluated the safety and anti-retroviral activity of raltegravir 1,200 mg once daily + emtricitabine (+) tenofovir disoproxil fumarate vs. raltegravir 400 mg twice daily, in combination with emtricitabine (+) tenofovir disoproxil fumarate, in treatment-naïve HIV-infected patients with HIV RNA > 1,000 copies/mL.
Blod og lymfesystem Ikke almindelig Anæmi, jernmangelanæmi, smerter i lymfeknuder, lymfadenopati, neutropeni, trombocytopeni
Uncommon anaemia, iron deficiency anaemia, lymph node pain, lymphadenopathy, neutropenia, thrombocytopenia
Øvrige indholdsstoffer: lactosemonohydrat; mikrokrystallinsk cellulose; calciumphosphat, dibasisk, vandfrit; hypromellose 2208; poloxamer 407; natriumstearylfumarat og magnesiumstearat.
The other ingredients are: lactose monohydrate, microcrystalline cellulose, calcium phosphate dibasic anhydrous, hypromellose 2208, poloxamer 407, sodium stearyl fumarate, and magnesium stearate.
Spædbørn og småbørn i alderen 4 uger til under 2 år Raltegravir er også blevet undersøgt hos 26 hiv-1-inficerede spædbørn og småbørn i alderen 4 uger til under 2 år i kombination med andre antiretrovirale midler i IMPAACT P1066 (se pkt.
Infants and toddlers 4 weeks to less than 2 years of age Raltegravir has also been studied in 26 HIV-1 infected infants and toddlers 4 weeks to less than 2 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
Tyggetabletten med appelsin-banansmag er oval, lys orange, med delekærv på begge sider, og mærket med MSD-virksomhedslogo og "477" på den ene side og ingen mærkning på den anden side.
The orange-banana flavoured chewable tablet is oval-shaped, pale orange coloured, scored on both sides with the MSD corporate logo and "477" on one side and without inscription on the other side.
SEDATIVA midazolam (raltegravir 400 mg to gange dagligt)
SEDATIVE midazolam (raltegravir 400 mg Twice Daily)
• Svimmelhed, hovedpine
• feeling dizzy; headache
Evidens for klinisk virkning af raltegravir blev baseret på analyserne af 96-ugers data fra to randomiserede, dobbeltblindede, placebokontrollerede studier (BENCHMRK 1 og BENCHMRK 2, Protokol 018 og 019) hos antiretrovirale behandlingserfarne hiv-1 inficerede voksne patienter, analysen fra 240-ugers data fra et randomiseret, dobbeltblindet, aktivt kontrolleret studie (STARTMRK, Protokol 021) hos antiretrovirale behandlingsnaive hiv-1 inficerede voksne patienter og analysen af 96-ugers data fra et randomiseret, dobbeltblindet, aktivt kontrolleret studie (ONCEMRK, Protokol 292) hos antiretrovirale behandlingsnaive hiv-1 inficerede voksne patienter.
The evidence of efficacy of raltegravir was based on the analyses of 96-week data from two randomised, double-blind, placebo-controlled trials (BENCHMRK 1 and BENCHMRK 2, Protocols 018 and 019) in antiretroviral treatment-experienced HIV-1 infected adult patients, the analysis of 240-week data from randomised, double-blind, active-control trial (STARTMRK, Protocol 021) in antiretroviral treatment-naïve HIV-1 infected adult patients and the analysis of 96-week data from randomised, double-blind, active-control trial (ONCEMRK, Protocol 292) in antiretroviral treatment-naïve HIV-1 infected adult patients.
Raltegravir to gange dagligt er blevet undersøgt hos 126 antiretrovirale behandlingserfarne hiv-1inficerede børn og unge i alderen 2 til 18 år i kombination med andre antiretrovirale lægemidler i IMPAACT P1066 (se pkt.
Raltegravir twice daily has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 to 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
• Gener i brystet, kuldegysninger, hævelser i ansigtet, anspændthed, generel utilpashed, hævet hals, hævede hænder, ankler eller fødder, smerter
• chest discomfort; chills; swelling of face; feeling jittery; generally feeling unwell; neck mass; swelling of hands, ankles or feet; pain
Evidens for klinisk effekt af raltegravir blev baseret på analyserne af 96-ugers data fra to randomiserede, dobbeltblindede, placebokontrollerede studier (BENCHMRK 1 og BENCHMRK 2, Protokol 018 og 019) hos antiretrovirale behandlingserfarne hiv-1 inficerede voksne patienter samt analysen fra 240-ugers data fra et randomiseret, dobbeltblindet, aktivt kontrolleret studie (STARTMRK, Protokol 021) hos antiretrovirale behandlingsnaive hiv-1 inficerede voksne patienter.
The evidence of efficacy of raltegravir was based on the analyses of 96-week data from two randomised, double-blind, placebo-controlled trials (BENCHMRK 1 and BENCHMRK 2, Protocols 018 and 019) in antiretroviral treatment-experienced HIV-1 infected adult patients and the analysis of 240-week data from a randomised, double-blind, active-control trial (STARTMRK, Protocol 021) in antiretroviral treatment-naïve HIV-1 infected adult patients.
* Den vægtbaserede doseringsanbefaling for tyggetabletten og den orale suspension i 10 ml vand er baseret på ca. 6 mg/kg/dosis to gange dagligt (se pkt.
1.5 x 100 mg twice daily *The weight-based dosing recommendation for the chewable tablet, and oral suspension in 10mL of water is based on approximately 6 mg/kg/dose twice daily (see section 5.2).
Behandlingserfarne voksne patienter (400 mg to gange dagligt) BENCHMRK 1 og BENCHMRK 2 (randomiserede, dobbeltblindede, placebokontrollerede multicenterstudier) vurderede sikkerheden og den antiretrovirale aktivitet af raltegravir 400 mg to gange dagligt versus placebo i en kombination med OBT hos hiv-inficerede patienter, i alderen 16 år og ældre, der har dokumenteret resistens over for mindst ét lægemiddel i hver af de 3 klasser (NRTIere, NNRTIere, PIere) af antiretroviral terapi.
Treatment-experienced adult patients (400 mg twice daily) BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled trials) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. placebo in a combination with optimised background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 drug in each of 3 classes (NRTIs, NNRTIs, PIs) of anti-retroviral therapies.
Dosisjustering af raltegravir eller midazolam er ikke nødvendig.
No dosage adjustment required for raltegravir or midazolam.
Resultater af uge 48- og 96-analyser
Results 48-week and 96-week analyses
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Tyggetablet 100 mg
Chewable tablet 100 mg
Dosisjustering af raltegravir eller etravirin er ikke nødvendig.
No dose adjustment required for raltegravir or etravirine.
Samtidig administration af raltegravir og aluminiumog/eller magnesiumholdige antacida frarådes (se pkt.
Co-administration of raltegravir with aluminium and/or magnesium antacids is not recommended (see section 4.5).
STARTMRK (randomiseret, dobbeltblindet, aktivt kontrolleret multicenterstudie) vurderede sikkerhed og antiretroviral aktivitet af raltegravir 400 mg to gange dagligt versus efavirenz 600 mg ved sengetid i en kombination med emtricitabin (+) tenofovirdisoproxilfumarat hos behandlingsnaive hiv-inficerede patienter med hiv-RNA >5.000 kopier/ml.
STARTMRK (multi-centre, randomised, double-blind, active-control trial) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. efavirenz 600 mg at bedtime, in a combination with emtricitabine (+) tenofovir disoproxil fumarate, in treatment-naïve HIV-infected patients with HIV RNA > 5,000 copies/mL.
2 x 100 mg to gange dagligt
2 x 100 mg twice daily
Sådan skal du tage Isentress
How to take Isentress
Tyggetabletten med appelsin-banansmag er rund, lysegul, mærket med MSD-virksomhedslogo og "473" på den anden side.
The orange-banana flavoured chewable tablet is round and pale yellow, marked with the MSD corporate logo on one side and “473” on the other side.
ISENTRESS 25 mg tyggetabletter ISENTRESS 100 mg tyggetabletter.
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets
Karton til 400 mg filmovertrukne tabletter
Carton for 400 mg film-coated tablets
), median [interval] CD4-procent, median [interval] Hiv-1 RNA >100.000 kopier/ml CDC hiv-kategori B eller C Tidligere antiretroviral behandling iht.
), median [range] CD4 percent, median [range] HIV-1 RNA >100,000 copies/mL CDC HIV category B or C Prior ART Use by Class NNRTI NRTI PI
Bivirkningen rabdomyolyse blev rapporteret med hyppigheden ikke almindelig i forbindelse med brug af raltegravir 400 mg to gange dagligt efter markedsføring.
Rhabdomyolysis was an uncommonly reported serious adverse reaction in post-marketing use of raltegravir 400 mg twice daily.
Skift til raltegravir (400 mg to gange dagligt)
Switch to raltegravir (400 mg twice daily)
Flaske til ISENTRESS 600 mg filmovertrukne tabletter
Bottle for ISENTRESS 600 mg film-coated tablets
Ved den prognostiske analyse blev virologisk svigt analyseret som "carry forward" for procent med henholdsvis < 400 og ≤ 50 kopier/ml.
For analysis by prognostic factors, virologic failures were carried forward for percent < 400 and 50 copies/mL.
Nukleoside/tide reverse transkriptasehæmmere tenofovirdisoproxilfumarat (raltegravir 400 mg to gange dagligt)
Nucleoside/tide reverse transcriptase inhibitors tenofovir disoproxil fumarate (raltegravir 400 mg Twice Daily)
Antacida med aluminium og magnesium nedsætter raltegravirs plasmakoncentration.
Aluminium and magnesium containing antacids reduce raltegravir plasma levels.
Den filmovertrukne 600 mg tablet er oval, gul, med MSD-virksomhedslogo og "242" præget på den ene side og uden prægning på den anden side.
What Isentress looks like and contents of the pack The 600 mg film-coated tablet is oval-shaped, yellow, marked with MSD corporate logo and "242" on one side and plain on the other side.
Administration af raltegravir sammen med aluminiumog/eller magnesiumholdige antacida frarådes.
Co-administration of raltegravir with aluminium and/or magnesium containing antacids is not recommended.
• Herpesinfektion, fx helvedesild
• herpes infections including shingles
Enkeltdosisfoliepose til ISENTRESS 100 mg granulat til oral suspension - foliepose
Unit dose sachet for ISENTRESS 100 mg granules for oral suspension - foil sachet
Karton til 600 mg filmovertrukne tabletter
Carton for 600 mg film-coated tablets
raltegravir AUC  67% raltegravir C24t  26% raltegravir Cmax  16%
raltegravir AUC  67% raltegravir C24hr  26% raltegravir Cmax  16%
Lys orange, oval tyggetablet med delekærv på begge sider, præget med MSD-virksomhedslogo og "477" på den ene side og ingen prægning på den anden side.
Pale orange coloured, oval shaped, chewable tablet scored on both sides with the MSD corporate logo and "477" on one side and without inscription on the other side.
25 mg tyggetabletter: Hver tyggetablet indeholder 25 mg raltegravir (som kalium).
25 mg chewable tablets: Each chewable tablet contains 25 mg of raltegravir (as potassium).
60 tyggetabletter
60 chewable tablets
Akne, alopeci, akneiform dermatitis, tør hud, erytem, tab af fedt i ansigtet, hyperhidrose, lipoatrofi, erhvervet lipodystrofi, lipohypertrofi, nattesved, prurigo, pruritus, generaliseret pruritus, makuløst udslæt, makulopapuløst udslæt, kløende udslæt, hudlæsioner, urticaria, xeroderma, StevensJohnsons syndrom, lægemiddeludslæt med eosinofili og systemiske symptomer (DRESS)
Uncommon acne, alopecia, dermatitis acneiforme, dry skin, erythema, facial wasting, hyperhidrosis, lipoatrophy, lipodystrophy acquired, lipohypertrophy, night sweats, prurigo, pruritus, pruritus generalised, rash macular, rash maculopapular, rash pruritic, skin lesion, urticaria, xeroderma, Stevens Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS)
Procent hiv-RNA < 50 kopier/ml (95% CI) Alle patienter
Percent HIV-RNA < 50 copies/mL (95 % CI) All patients
Norelgestromin (raltegravir 400 mg to gange dagligt)
Norelgestromin (raltegravir 400 mg Twice Daily)
Isentress 25 mg tyggetabletter Isentress 100 mg tyggetabletter raltegravir
Isentress 25 mg chewable tablets Isentress 100 mg chewable tablets raltegravir
100 mg tyggetabletter: Hver tyggetablet indeholder 100 mg raltegravir (som kalium).
100 mg chewable tablets: Each chewable tablet contains 100 mg of raltegravir (as potassium).
ISENTRESS 100 mg granulat til oral suspension
ISENTRESS 100 mg granules for oral suspension
raltegravir AUC  72% raltegravir C24t  48% raltegravir Cmax  74%
raltegravir AUC  72% raltegravir C24 hr  48% raltegravir Cmax  74%
Raltegravir 600 mg (1.200 mg en gang dagligt) (N = 531)
Raltegravir 600 mg (1,200 mg once daily)
Administration af atazanavir sammen med raltegravir 1.200 mg en gang dagligt øgede raltegravirs plasmakoncentration signifikant.
Co-administration of atazanavir with raltegravir 1,200 mg once daily significantly increased plasma levels of raltegravir; therefore, co-administration of raltegravir 1,200 mg once daily and atazanavir is not recommended.
1,5 x 100 mg † to gange dagligt
1.5 x 100 mg † twice daily
OPIOIDANALGETIKA methadon (raltegravir 400 mg to gange dagligt)
OPIOID ANALGESICS methadone (raltegravir 400 mg Twice Daily)
Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, du er i tvivl om.
You should check with your doctor, pharmacist or nurse if you are not sure.
Hvis du har taget for meget Isentress
If you take more Isentress than you should
Flaske til ISENTRESS 400 mg - filmovertrukne tabletter
Bottle for ISENTRESS 400 mg film-coated tablets
Alle patienter Karakteristika ved baseline Hiv-RNA > 100.000 kopier/ml ≤ 100.000 kopier/ml
Baseline Characteristic HIV-RNA > 100,000 copies/mL
Ikke almindelig Nyresvigt, nefritis, nefrolitiasis, nykturi, nyrecyste, nedsat nyrefunktion, tubulo-interstitiel nefritis
Renal and urinary disorders Uncommon renal failure, nephritis, nephrolithiasis, nocturia, renal cyst, renal impairment, tubulointerstitial nephritis
Tabel 5 viser de farmakokinetiske parametre for 400 mg tabletten, tyggetabletten og granulatet til oral suspension ud fra kropsvægt.
Table 5 displays pharmacokinetic parameters in the 400 mg tablet, the chewable tablet, and the granules for oral suspension, by body weight.
antacidum med calciumcarbonat (raltegravir 400 mg to gange dagligt)
calcium carbonate antacid (raltegravir 400 mg Twice Daily)
Antal tyggetabletter
Number of chewable tablets